Search results
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
The new guidelines provide risk thresholds for clinical action (Table 1) and establish risk estimates for the development of cervical intraepithelial neoplasia grade 3 (CIN 3), adenocarcinoma in situ, or cancer (ie, CIN 3+) for different combinations of test results.
19 wrz 2024 · Read the new ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The updated management guidelines aim to: Allow for a more complete and precise estimation of risk
Screening Guidelines. Screening recommendations for the identification of precursors and prevention of cervical cancer. View Screening Guidelines. Management Guidelines & the Enduring Guidelines Process. Risk-based Management Guidelines for the abnormal screening results, including post-colposcopy or post-treatment scenarios.
Management includes fertility sparing treatment, early and locally advanced cervical cancer, invasive cervical cancer diagnosed on a simple hysterectomy (SH) specimen, cervical cancer in pregnancy, rare tumors, recurrent and metastatic diseases.
Cervical cancer screening recommendations have changed since the 2012 guidelines. For example, primary HPV is a screening option for patients 25 years of age and older. Updated guidelines were needed to incorporate these changes.
GUIDING PRINCIPLES. METHODS. SUB-SECTION. D.1 Process and Timeline. D.2 Choice of CIN3+ as Main Clinical Endpoint for Risk Estimates. D.3 Multiple Data Sets Used to Validate Risks. D.4 Estimation of Risks. D.5 Assigning Combinations of Test Results to Clinical Actions. D.6 Rating the Recommendations.
